Alivus Life Sciences Ltd
ALIVUS
Company Profile
Business description
Alivus Life Sciences Ltd, formerly Glenmark Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disease, pain management, diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas.
Contact
470, Cardinal Gracious Road
4th Floor, OIA House
Andheri (East)
MumbaiMH400 099
INDT: +91 2268297979
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
2,014
Stocks News & Analysis
stocks
Another incredible quarter from Microsoft
We were wrong when we thought last quarter would be hard to top.
stocks
10 best US dividend aristocrats to buy now—including a surprise outperformer
These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks
Leading ASX players in this field look materially overvalued
We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,999.00 | 16.40 | -0.18% |
| CAC 40 | 7,771.97 | 89.99 | -1.14% |
| DAX 40 | 24,065.47 | 196.75 | -0.81% |
| Dow JONES (US) | 44,226.91 | 234.37 | -0.53% |
| FTSE 100 | 9,132.81 | 4.13 | -0.05% |
| HKSE | 24,773.33 | 403.60 | -1.60% |
| NASDAQ | 21,141.02 | 11.35 | 0.05% |
| Nikkei 225 | 41,069.82 | 415.12 | 1.02% |
| NZX 50 Index | 12,823.74 | 32.23 | -0.25% |
| S&P 500 | 6,348.75 | 14.15 | -0.22% |
| S&P/ASX 200 | 8,742.80 | 13.60 | -0.16% |
| SSE Composite Index | 3,573.21 | 42.51 | -1.18% |